REG - Physiomics PLC - Issue of Equity

PhysiomicsAnnouncement

19/01/2022 12:35

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220119:nRSS9812Ya&default-theme=true

RNS Number : 9812Y  Physiomics PLC  19 January 2022

19 January 2022

Physiomics plc

("Physiomics" or "the Company")

 

Issue of Equity

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, announces that following the receipt of a notice of exercise of
employee options, 90,000 ordinary shares of 0.4p each in the Company
("Ordinary Shares") (the "Options Shares") will be issued to an employee at an
exercise price of 3.16p per option.

 

Application will be made for the Option Shares, which will rank pari
passu with the Company's existing Ordinary Shares, to be admitted to trading
on AIM, and dealings in the Option Shares are expected to commence on 25
January 2022 ("Admission").  Following Admission, the total number of
Ordinary Shares in issue will increase to 97,424,778.

 

For the purposes of the Financial Services Authority's Disclosure Guidance and
Transparency Rules (the "DTRs"), the issued ordinary share capital of the
Company following Admission will consist of 97,424,778 Ordinary Shares with
voting rights attached (one vote per Ordinary Share).  There are no Ordinary
Shares held in treasury.  This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they will
determine whether they are required to notify their interests in, or a change
to their interest in, Physiomics under the DTRs.  The Company's share capital
additionally comprises 2,481,657,918 deferred shares of 0.036p each which are
not quoted and to which no voting rights attach.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEAAFNFFFAEFA